BRAFV600E mutation analysis by immunohistochemistry in patients with thoracic metastases from colorectal cancer
References (42)
- et al.
The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients
Ann Oncol
(2010) - et al.
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
Lancet Oncol
(2010) - et al.
Detection of the BRAF V600E mutation in serous ovarian tumors: a comparative analysis of immuno-histochemistry with a mutation-specific monoclonal antibody and allele-specific PCR
Hum Pathol
(2013) - et al.
Diagnostic value of immunohistochemistry for the detection of the BRAFV600E mutation in primary lung adenocarcinoma Caucasian patients
Ann Oncol
(2013) - et al.
Sensitive sequencing method for KRAS mutation detection by Pyrosequencing
J Mol Diagn
(2005) - et al.
K-ras mutations and benefit from cetuximab in advanced colorectal cancer
N Engl J Med
(2008) - et al.
Systematic review of pharmaco-genetic testing for predicting clinical benefit to anti-EGFR therapy in metastatic colorectal cancer
Am J Cancer Res
(2011) - et al.
BRAF mutation in metastatic colorectal cancer
N Engl J Med
(2009) - et al.
Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer
J Clin Oncol
(2008) - et al.
Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer
J Clin Oncol
(2009)
BRAF V600E mutation and resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer: a meta-analysis
Mol Biol Rep
Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer
Br J Cancer
Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer
N Engl J Med
BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer
Br J Cancer
Predictive and prognostic role of BRAF mutation in patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: a meta-analysis
J Dig Dis
KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial
J Clin Oncol
Application of a BRAF V600E mutation-specific antibody for the diagnosis of hairy cell leukemia
Am J Surg Pathol
Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody
Acta Neuropathol
Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases
Acta Neuropathol
Immunohistochemical detection of the BRAF V600E-mutated protein in papillary thyroid carcinoma
Am J Surg Pathol
Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma
Am J Surg Pathol
Cited by (10)
Orbital angular momentum mode demodulation with neural network-assisted coherent nanophotonic circuits
2023, Optics CommunicationsBRAF V600E mutation-specific antibody: A review
2015, Seminars in Diagnostic PathologyCitation Excerpt :Cases with signet-ring-cell morphology were reported to produce both false–positive and negative IHC results.77,82 Also, background staining was reported in nuclei of normal colonic mucosa, smooth muscle, mucin, and nerve bundles.77,79 All of these findings indicate that careful IHC interpretation is required, though interobserver reproducibility was reported in one study as virtually perfect.86
Utility of BRAF V600E Immunohistochemistry Expression Pattern as a Surrogate of BRAF Mutation Status in 154 Patients with Advanced Melanoma
2015, Human PathologyCitation Excerpt :Arguing against this is that there was no apparent difference in the allele frequencies observed in heterogeneous compared with homogeneous samples. Tumor heterogeneity for BRAF V600E IHC expression has also been reported in approximately 10% of thyroid cases and 1.5% of colorectal cancers cases [27–29]. Correlation with heterogeneous BRAF V600E IHC expression as a surrogate for the BRAF V600E mutation may be tumor dependent because there is a relative high rate of correlation with this pattern of labeling and the presence of BRAF V600E mutation in melanomas and thyroid carcinomas, but not in colorectal carcinomas [9,27,29].
Interest of theranostic immunohistochemistry in non-small cell lung cancer : Applications and current limits
2015, Revue Francophone des Laboratoires